LONDON, Jan. 19, 2022
/PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the
multinational pharmaceutical company, announces that its venture
capital arm, Hikma Ventures has led a $11
million USD round of financing for NuvoAir, a leading
digital health company for chronic disease management and
decentralized clinical trials that focuses on complex patients,
initially targeting respiratory conditions such as COPD and asthma.
The investment is an extension of the Series A round that was
previously announced by NuvoAir in June
2021. This most recent financing, which also saw
participation from a strategic investor and other existing
investors, brings the total Series A round to $25 million USD.
The NuvoAir Home platform blends connected devices with
high-touch care coordination and coaching services to enable
patients and their providers to proactively manage chronic
conditions, resulting in better outcomes and lower costs. NuvoAir's
care teams are designed to work in close collaboration with a
partner's existing care infrastructure to utilize NuvoAir's
technology and data to personalize the care of each member.
NuvoAir's patient-centric approach also underlies its decentralized
clinical trials solution. By bringing the trial to the patient's
home, NuvoAir can dramatically improve their experience, reducing
the burden for both patients and study sites.
"Healthcare is far too confusing and fragmented to navigate,
particularly for complex patients who often suffer multiple
comorbidities," said Gary Kurtzman,
Chairman of NuvoAir. "The solution lies in redesigning the
experience around the patient, thereby providing a more empathetic
and coordinated approach to their care."
"We are really excited to have Hikma Ventures join our existing
investors to help us expand our unique service model and technology
to support a truly patient focused approach to delivering clinical
care and clinical trials," commented Lorenzo Consoli, Founder and CEO of NuvoAir.
"Hikma is a growing provider of medicines to patients suffering
from respiratory conditions. We are excited to build on that
important work by supporting the development of NuvoAir's platform,
which is enabling better and more proactive care by providing all
relevant stakeholders with access to high quality data," said
Faisal Al-Husry, Associate at Hikma
Ventures.
"This is our second investment in the respiratory space which is
a key strategic area for Hikma," said Lana
Ghanem, Managing Director of Hikma Ventures. "We are looking
forward to working closely with our co-investors and the NuvoAir
team to help advance the platform and expand its reach, especially
in territories strategically relevant for Hikma."
NuvoAir will be using the proceeds of this financing to expand
its platform and team, accelerate the launch of its clinical
services within risk-bearing providers and Health Plans, and launch
new clinical trial partnerships
globally.
Investor
Enquiries:
Hikma
Ventures
Lana
Ghanem
Managing Director,
Hikma Ventures
|
lana@hikmaventures.com
+962 6 580 3100
|
|
|
Hikma
Pharmaceuticals PLC
Susan
Ringdal
EVP, Strategic
Planning and Global Affairs
|
+44 (0)20 7399 2760/
+44 7776 477050
uk-investors@hikma.uk.com
|
|
|
Media:
Steve
Weiss
David
Belian
US Communications and
Public Affairs
|
+1 732 788
8279
+1 848 254
4875
uscommunications@hikma.com
|
About Hikma
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC:
HKMPY) (rated BBB-/stable S&P and BBB-/stable Fitch)
Hikma helps put better health within reach every day for millions
of people around the world. For more than 40 years, we've been
creating high-quality medicines and making them accessible to the
people who need them. Headquartered in the UK, we are a global
company with a local presence across the
United States (US), the Middle
East and North Africa
(MENA) and Europe, and we use our
unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers, and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,600 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner,
and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more
information, please visit: www.hikma.com
About Hikma Ventures
Founded in August 2015, Hikma Ventures operates as the
corporate venture capital arm of Hikma Pharmaceuticals. Hikma
Ventures invests in global start-ups where Hikma's expertise can
accelerate revenue growth and enhance value creation by providing
ventures with access to the resources of a multinational
pharmaceutical company. For more information, please visit
www.hikmaventures.com.
About NuvoAir
With offices in Boston, MA,
and Stockholm, Sweden, NuvoAir is a leading digital
health company for chronic disease management and decentralized
clinical trials. NuvoAir delivers a more continuous,
relationship based, coordinated and human centric experience to
individuals with complex conditions, with initial focus on
respiratory diseases. NuvoAir partners with health plans and
risk-bearing providers with the goal to fully align the incentives
under a value-based care framework. For more information, please
visit https://www.nuvoair.com/.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hikma-ventures-leads-series-a-extension-in-nuvoair-to-support-its-platform-for-patient-centric-care-and-clinical-trials-301463779.html
SOURCE Hikma Pharmaceuticals USA Inc.